Discovering the anticancer potential of non-oncology drugs by systematic viability profilingSteven M. Corsello, Todd R. Golub, Rohith T. Nagari et al.|Nature Cancer|2020Cited by 880
Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneityGabriela Sarti Kinker, Itay Tirosh, Alissa Greenwald et al.|Nature Genetics|2020Cited by 465
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
Massively parallel pooled screening reveals genomic determinants of nanoparticle deliveryNatalie Boehnke, Paula T. Hammond, Joelle P. Straehla et al.|Science|2022Cited by 195